196 related articles for article (PubMed ID: 29967951)
21. Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex.
Chou JY; Matern D; Mansfield BC; Chen YT
Curr Mol Med; 2002 Mar; 2(2):121-43. PubMed ID: 11949931
[TBL] [Abstract][Full Text] [Related]
22. Glycogen storage disease type I and G6Pase-β deficiency: etiology and therapy.
Chou JY; Jun HS; Mansfield BC
Nat Rev Endocrinol; 2010 Dec; 6(12):676-88. PubMed ID: 20975743
[TBL] [Abstract][Full Text] [Related]
23. Neutrophil stress and apoptosis underlie myeloid dysfunction in glycogen storage disease type Ib.
Kim SY; Jun HS; Mead PA; Mansfield BC; Chou JY
Blood; 2008 Jun; 111(12):5704-11. PubMed ID: 18420828
[TBL] [Abstract][Full Text] [Related]
24. Functional analysis of mutations in the glucose-6-phosphate transporter that cause glycogen storage disease type Ib.
Chen SY; Pan CJ; Lee S; Peng W; Chou JY
Mol Genet Metab; 2008 Dec; 95(4):220-3. PubMed ID: 18835800
[TBL] [Abstract][Full Text] [Related]
25. Glycogen storage disease type 1b: an early onset severe phenotype associated with a novel mutation (IVS4) in the glucose 6-phosphate translocase (SLC37A4) gene in a Turkish patient.
Oguz MM; Aykan E; Yilmaz G; Aytekin C; Karaer K; Açoğlu EA
Genet Couns; 2014; 25(4):389-94. PubMed ID: 25804016
[TBL] [Abstract][Full Text] [Related]
26. The molecular basis of type 1 glycogen storage diseases.
Chou JY
Curr Mol Med; 2001 Mar; 1(1):25-44. PubMed ID: 11899241
[TBL] [Abstract][Full Text] [Related]
27. A novel SLC37A4 missense mutation in GSD-Ib without hepatomegaly causes enhanced leukocytes endoplasmic reticulum stress and apoptosis.
Xu Q; Tang H; Duan L; Zuo X; Shi X; Li Y; Zhao H; Zhang H
Mol Genet Genomic Med; 2021 Jan; 9(1):e1568. PubMed ID: 33280276
[TBL] [Abstract][Full Text] [Related]
28. Dapagliflozin Prevents Kidney Glycogen Accumulation and Improves Renal Proximal Tubule Cell Functions in a Mouse Model of Glycogen Storage Disease Type 1b.
D'Acierno M; Resaz R; Iervolino A; Nielsen R; Sardella D; Siccardi S; Costanzo V; D'Apolito L; Suzumoto Y; Segalerba D; Astigiano S; Perna AF; Capasso G; Eva A; Trepiccione F
J Am Soc Nephrol; 2022 Oct; 33(10):1864-1875. PubMed ID: 35820785
[TBL] [Abstract][Full Text] [Related]
29. A molecular link between the common phenotypes of type 1 glycogen storage disease and HNF1alpha-null mice.
Hiraiwa H; Pan CJ; Lin B; Akiyama TE; Gonzalez FJ; Chou JY
J Biol Chem; 2001 Mar; 276(11):7963-7. PubMed ID: 11121425
[TBL] [Abstract][Full Text] [Related]
30. Novel mutation of SLC37A4 in a glycogen storage disease type Ib patient with neutropenia, horseshoe kidney, and arteriovenous malformation: a case report.
Meimand SE; Azizi G; Yazdani R; Sanadgol N; Rezaei N
Immunol Res; 2023 Feb; 71(1):107-111. PubMed ID: 36129616
[TBL] [Abstract][Full Text] [Related]
31. Human variant glucose-6-phosphate transporter is active in microsomal transport.
Lin B; Pan CJ; Chou JY
Hum Genet; 2000 Nov; 107(5):526-9. PubMed ID: 11140953
[TBL] [Abstract][Full Text] [Related]
32. Mutations in the glucose-6-phosphate transporter (G6PT) gene in patients with glycogen storage diseases type 1b and 1c.
Galli L; Orrico A; Marcolongo P; Fulceri R; Burchell A; Melis D; Parini R; Gatti R; Lam C; Benedetti A; Sorrentino V
FEBS Lett; 1999 Oct; 459(2):255-8. PubMed ID: 10518030
[TBL] [Abstract][Full Text] [Related]
33. The signature motif in human glucose-6-phosphate transporter is essential for microsomal transport of glucose-6-phosphate.
Pan CJ; Chen LY; Mansfield BC; Salani B; Varesio L; Chou JY
Hum Genet; 2003 Apr; 112(4):430-3. PubMed ID: 12560945
[TBL] [Abstract][Full Text] [Related]
34. Successful use of empagliflozin to treat neutropenia in two G6PC3-deficient children: Impact of a mutation in SGLT5.
Boulanger C; Stephenne X; Diederich J; Mounkoro P; Chevalier N; Ferster A; Van Schaftingen E; Veiga-da-Cunha M
J Inherit Metab Dis; 2022 Jul; 45(4):759-768. PubMed ID: 35506446
[TBL] [Abstract][Full Text] [Related]
35. Molecular genetics of type 1 glycogen storage disease.
Janecke AR; Mayatepek E; Utermann G
Mol Genet Metab; 2001 Jun; 73(2):117-25. PubMed ID: 11386847
[TBL] [Abstract][Full Text] [Related]
36. DBS are suitable for 1,5-anhydroglucitol monitoring in GSD1b and G6PC3-deficient patients taking SGLT2 inhibitors to treat neutropenia.
Dewulf JP; Chevalier N; Marie S; Veiga-da-Cunha M
Mol Genet Metab; 2023 Nov; 140(3):107712. PubMed ID: 38353183
[TBL] [Abstract][Full Text] [Related]
37. New insights into the organisation and intracellular localisation of the two subunits of glucose-6-phosphatase.
Soty M; Chilloux J; Casteras S; Grichine A; Mithieux G; Gautier-Stein A
Biochimie; 2012 Mar; 94(3):695-703. PubMed ID: 21983240
[TBL] [Abstract][Full Text] [Related]
38. Historical highlights and unsolved problems in glycogen storage disease type 1.
Moses SW
Eur J Pediatr; 2002 Oct; 161 Suppl 1():S2-9. PubMed ID: 12373565
[TBL] [Abstract][Full Text] [Related]
39. Genotype/phenotype correlation in glycogen storage disease type 1b: a multicentre study and review of the literature.
Melis D; Fulceri R; Parenti G; Marcolongo P; Gatti R; Parini R; Riva E; Della Casa R; Zammarchi E; Andria G; Benedetti A
Eur J Pediatr; 2005 Aug; 164(8):501-8. PubMed ID: 15906092
[TBL] [Abstract][Full Text] [Related]
40. SGLT5 is the renal transporter for 1,5-anhydroglucitol, a major player in two rare forms of neutropenia.
Diederich J; Mounkoro P; Tirado HA; Chevalier N; Van Schaftingen E; Veiga-da-Cunha M
Cell Mol Life Sci; 2023 Aug; 80(9):259. PubMed ID: 37594549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
